Neurol. praxi. 2024;25(5):353-356 | DOI: 10.36290/neu.2024.033

Severity of cardiac involvement in Emery­‑Dreifuss muscular dystrophy

doc. MUDr. Edvard Ehler, CSc.1, prof. MUDr. Ivana Štětkářová, CSc., MHA2, doc. MUDr. Ing. Karol Čurila, Ph.D.3
1 Neurologická klinika FZS Univerzity Pardubice a PKN, Pardubice
2 Neurologická klinika 3. LF UK a FNKV, Praha
3 Kardiologická klinika 3. LF UK a FNKV, Praha

Emery-Dreifuss muscular dystrophy (EDMD) belongs to a rare genetic diseases with disturbances of the genes encoding nuclear membrane proteins. Neurological symptoms are less pronounced and not too limiting for EDMD patients; however, dominant cardiac symptoms with conduction impairment (AV block, atrial arrhythmias) and/or cardiomyopathy are the most serious manifestations of EDMD. We present 10 patients with EDMD, pointing out the variability and severity of cardiac problems, including long-term medical care within the approach of the multidisciplinary medical team.

Keywords: muscle dystrophy, muscle contractures, cardiac arrhythmias, cardiomyopathy.

Received: May 8, 2024; Revised: May 8, 2024; Accepted: May 8, 2024; Prepublished online: May 8, 2024; Published: November 19, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ehler E, Štětkářová I, Čurila K. Severity of cardiac involvement in Emery­‑Dreifuss muscular dystrophy. Neurol. praxi. 2024;25(5):353-356. doi: 10.36290/neu.2024.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 19.11.2025

    References

    1. Cannie DE, Syrris P, Protonotarios A, et al. Emery­‑Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end­‑stage heart failure. Eur Heart J. 2023;44(48):5064-5073. Go to original source... Go to PubMed...
    2. Heller SA, Shih R, Kalra R, Kang PB. Emery­‑Dreifuss muscular dystrophy. Muscle Nerve. 2020;61(4):436-448. Go to original source... Go to PubMed...
    3. Homma K, Nagata E, Hanano H, et al. A Young Patient with Emery­‑Dreifuss Muscular Dystrophy Treated with Endovascular Therapy for Cardioembolic Stroke: A Case Report. Tokai J Exp Clin Med. 2018;43(3):103-105.
    4. Kashyap N, Nikhanj A, Gagnon LR, et al. Cardiac manifestations and clinical management of X­‑linked Emery­‑Dreifuss muscular dystrophy: a case series. Eur Heart J Case Rep. 2023;7(1):ytad013. Go to original source... Go to PubMed...
    5. Marchel M, Madej­‑Pilarczyk A, Steckiewicz R, et al. Predictors of mortality and cardiovascular outcomes in Emery­‑Dreifuss muscular dystrophy in a long­‑term follow­‑up. Kardiol Pol. 2021;79(12):1335-1342. Go to original source... Go to PubMed...
    6. Muchir A, Worman HJ. Emery­‑Dreifuss muscular dystrophy. Curr Neurol Neurosci Rep. 2007;7(1):78-83. Go to original source... Go to PubMed...
    7. Prax T, Ehler E, Ungermann L, Štětkářová I. Okluze velkých mozkových tepen u nemocné se svalovou dystrofií Emery­‑Dreifuss. Cesk Slov Neurol N. 2021;84(5): 491-492. Go to original source...
    8. Wang S, Peng D. Cardiac Involvement in Emery­‑Dreifuss Muscular Dystrophy and Related Management Strategies. Int Heart J. 2019;60(1):12-18. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.